Brian GM Durie. Black Swan Research Initiative (BSRI) Purpose
|
|
- Dana Adams
- 6 years ago
- Views:
Transcription
1 Black Swan Research Initiative Brian GM Durie Saturday August 22, Black Swan Research Initiative (BSRI) Purpose The Black Swan Research Initiative (BSRI) is a global collaborative approach Which uses the most precise MRD testing To track myeloma at the lowest levels As a basis for treatment decisions To achieve a cure 2
2 Black Swan Research Initiative Where are we? What are the next steps? 3 Key Elements of BSRI 1. Early Diagnosis 2. MRD Assessment of Response 3. Clinical Trials 4
3 Step 1: Early Diagnosis BLACK SWAN RESEARCH INITIATIVE 5 Key New Publication recommends the implementation of these criteria in routine practice 6
4 New Criteria for Active Myeloma CRAB Criteria Calcium Renal Anemia Bone and/or Myeloma Defining Events 7 New Criteria for Active Myeloma Myeloma-Defining Events Creatinine clearance < 40 ml/min Bone marrow plasma cells 60% Serum Freelite ratio 100 Imaging evidence of active disease MDE >1 focal lesion on MRI New CRAB Positive PET/CT Lesions >5mm on WBLD CT 8
5 Step 2: Next Generation MRD Testing BLACK SWAN RESEARCH INITIATIVE 9 Going beyond the CR criteria with MRD monitoring < 5% PCs in bone marrow Negative IFE of serum and urine Disappearance of soft tissue plasmacytomas Cellular clonality Cellular production Cellular spread Immunohistochemistry ASO-PCR Next Generation Sequencing (NGS) Next Generation Flow (NGF) sflc Hevylite Sensitive M-spike measurement PET/CT WB-MRI 10
6 MRD monitoring in multiple myeloma using NGS Commercial Home-made 1. Extraction and quantification of gdna (qpcr) 2. VDJ, DJ,KDEL etc. PCR amplification with Biomed 2 primers 3. Ligation with barcodes 4. Sequencing, Ion Proton Platform Martinez-Lopez J, et al. 11 IMF/ EuroFlow Consortium Develop more sensitive and standardized flow method: Next Generation Flow (NGF) Ideal antibody cocktails: now sensitive at and 10-color cross panel validation Multi-dimensional analysis software: now 12 minutes! 12
7 NGF Antibody Panels Panel Tube BV421 BV510 BV605 FITC PE PerCP Cy5.5 PE Cy7 APC APC A700 APC C color 1 CD117 CD81 CD138 CD27 CD38 CD56 CD45 CD19 2 CyIgk CyIgl 10-color 1 CD138 CD27 CyIgl CD38 CD56 CD45 CD19 CD117 CyIgk CD81 13 Current Use of NGF: 8 Colour Gold Standard U.S. MAYO MDAH UAMS (MIRT) U of Chicago Columbia (NY) Mount Sinai (NY) Carolinas Roswell Park Europe Latin America Japan Singapore China Australia Spain France (IFM) Italy (Palumbo) Netherlands (Hovon) Germany Turkey Brazil Tokyo National University Beijing, Tianjin, Shanghai Melbourne 14
8 MRD monitoring in MM using NGF: ultra-sensitivity Next-generation flow - + Total NGS - 9/14 (64%) 2/14 (14%)* 11/14 (78%) + 0/14 (0%) 3/14 (22%) 3/14 (22%) Total 9/14 (64%) 5/14 (36%) NGS was applicable in 14/16 (88%) of MM cases 15 Current Use of NGF: 8 Color Gold Standard
9 NGF for MRD monitoring in MM: GEM2012MENOS65 (>400 tests) CR and MRD-negative 49% 49% MRD-positive % MRD-positive % MRD-positive % MRD 10-7 <1% + 51% 17 Iceberg Effect 49% % 20% 51% 8% % 10-5
10 NGF for MRD monitoring in MM: ultra-sensitivity 10 Patient % clonal PCs % MRD % MRD % MRD % MRD Diagnosis CR Induction HDT/ASCT Consolidation 19 Steps to Assess and Treat MRD Monitor or Maintain If negative If positive Develop specific Rx MoAb Studies Study Residual MRD Assess Relapse/ Resistant Disease MRD Assessment Car/Rev/Pom/ + Elo or DARA Alternate Rx 20
11 Newly-diagnosed symptomatic MM patients with an MGUS-like profile by Flow and GEP Phenotypic MGUS-like profile Molecular MGUS-like profile Symptomatic MM MGUS-like symptomatic MM (~10%) Paiva B, et al. Leukemia. 2013;27(10): Zhan et al. Blood. 2007;109: Survival for MGUS-like MM patients is independent of CR Less than CR should not be considered a sub-optimal response TTP 100 TTP Median: NR 59%@10y 80 Median: NR Median: NR 20 Median: 44 months 14%@10y 20 0 HR: 3.27 ; P < P = Time from diagnosis (months) Time from diagnosis (months) MGUS-like profile (n=59) MM-like profile (n=639) CR (n=26) < CR (n=33) Paiva B, et al. Leukemia. 2013;27(10):
12 MRD clonal PCs show de-regulated GEP compared to baseline clonal PCs B A S E L I N E M R D Paiva B, et al. Blood 2013;122(21): abstract 402 (oral presentation) 23 Proteasome inhibitor resistance-related genes PAAF1: proteasomal ATPase-associated factor 1 PSMA6: proteasome subunit, alpha type, 6 PSMB10: proteasome subunit, beta type, 10 POMP: proteasome maturation protein PSME1: proteasome activator subunit 1 PSMD10: proteasome 26S subunit, non-atpase, 10 PSMB6: proteasome subunit, beta type, 6 PSME3: proteasome activator subunit 3 PSMA2: proteasome subunit, alpha type, 2 Low Paiva B, et al. Blood 2013;122(21): abstract 402 (oral presentation) 24
13 PDL1 - PD1 axis is up-regulated after therapy at the MRD stage Amount of PD-L1 MFI-expression / PC P =.05 Percentage of cells with PD1 surface expression CD4 T-cells CD8 T-cells P < Normal PCs Clonal PCs 20 0 Paiva B, et al. Leukemia. 2015; doi: /leu Antigen/Receptor Targets T Cell NK KIR Cell CD 16 SLAM F7 CAR T cell PD-1 checkpoint inhibitor PD-L1 CD 28 CD 117 CD 45 CD 33 CD 20 CD 19 CD 19 4% LDL-R CD 46 CD 56 Lorvo/Dace CD 138 Inda CD 319 Elo (SLAM F7) CD 38 DARA/SAR/MOR % Measles VSV Monoclonal Antibodies Multiple Targets 26
14 Specific Targets Antigens Molecular 18% 36% PD-L1 CD 28 CD 117 CD 45 CD 33 CD 20 CD 19 4% CD 56 CD 138 CD 319 (SLAM F7) CD % BRAF 4% KRAS NRAS CCND1 DIS3 HOX A9 NFKB Hundreds of mutations, SNPs, and pathways 27 Transitioning from conventional CR Complete Response (CR) Negative serum and urine immunofixation <5% PCs in marrow MRD negative Flow negative MRD Sequencing negative MRD Imaging negative MRD Stringent Complete Response (scr) Normal FLC ratio No clonal plasma cells in marrow 28
15 New Criteria for MRD MRD-negative by Next-generation flow MRD-negative by Next-generation sequencing Imaging plus cellular MRD-negative Conventional CR PLUS Absence of phenotypically aberrant clonal plasma cells by nextgeneration flow cytometry on bone marrow aspirates using the EuroFlow standard operation procedure for MRD detection in MM (minimum sensitivity of 1 in 10 5 nucleated cells) Conventional CR +PLUS A clonotype was defined AND Less than 2 identical sequencing reads obtained after DNA sequencing of bone marrow aspirates using the Lymphosight platform (minimum sensitivity of 1 in 10 5 nucleated cells) MRD negative as defined above (MFC or sequencing) PLUS Disappearance of every area of increased tracer uptake found at baseline by PET/CT 29 Upcoming Trials NGF in Blood MGUS SMM MM Low MRD Status New Trial Options MRD NEG MGUS Signature CURE Trials Resistant MRD 30
16 CESAR Trial C urative E strategy S moldering A lto R isk HR SMM KRd x 6 cycles ASCT KRd x 2 cycles Rd x 2 years 31 ASCENT Trial Aggressive Smoldering Cure Evaluating Novel Rx Transplant HR SMM KRd + DARA x 4 cycles ASCT KRd + DARA x 4 cycles KRd + DARA x 4 cycles K DARA x 2 years 32
17 Patients with long-term survival have a unique immune signature Poor Maturation TAMs Myeloid-Dcs Plasmacytoid-Dcs T- Reg MO Numbers NK CD8 CD8 CD8 Inhibition NK N-Pcs B NK N-Pcs B B Bone Marrow Stromal Cells Bone Marrow Stromal Cells Bone Marrow Stromal Cells Pessoa de Magalhães RJ, et al. Haematologica. 2013;98(1): Forward Expectations and Plans Expanding cure fraction 2017 Documenting cure Validation of clinical correlates 2016 Expanding achievement of MRD-negative Studying MRD-positive; introducing Rx to eradicate Understanding MRD-negative Introducing new MRD blood test 2015 Cross correlate with NGS and imaging Now Standardized NGF test for bone marrow 34
18 35 36
Paris Seminar for Patients & Caregivers: BSRI 2017 On the Path to a Cure. Brian GM Durie Saturday, June 10, 2017
Paris Seminar for Patients & Caregivers: BSRI 2017 On the Path to a Cure Brian GM Durie Saturday, June 10, 2017 1 Black Swan: on the way to a cure Sustained low level disease Favorable immune signature
More informationMyeloma 101 Updates and Pain Management Perspectives
Myeloma 101 Updates and Pain Management Perspectives Brian GM Durie, MD Thursday, November 19 th, 2015 Topics for Discussion 1. What to expect from ASH 2015 a preview Research Clinical pearls : New 101
More informationHot Topic. Disclosures. None
Hot Topic Multiple Myeloma Testing at Mayo Medical Laboratories HOT TOPIC / 2017 MFMER 1 Our speaker for this program is Dragan Jevremovic, MD, PhD Assistant Professor, Division of Hematopathology at Mayo
More informationGuidelines for the diagnosis of Multiple Myeloma Ass.lec.: Dr. Karam T. Agha M.Sc.Pathology
Guidelines for the diagnosis of Multiple Myeloma 2014 By:British Committee for Standards in Haematology (BCSH) Ass.lec.: Dr. Karam T. Agha M.Sc.Pathology Diagnosis, prognostic factors and disease monitoring
More informationInternational Myeloma Foundation
Black Swan Research Initiative Towards the Cure for Myeloma Brian GM Durie Friday, July 25, 2014 The IMF Initiatives Black Swan Research Initiative Purpose The Black Swan Research Initiative is a global
More informationCongreso Nacional del Laboratorio Clínico 2016
Técnicas de alta sensibilidad en la detección de enfermedad mínima residual en Mieloma Múltiple J. Flores-Montero, MD, PhD Departamento de Medicina, Servicio Central de Citometría, Centro de Investigación
More informationRestrooms Cell phones on silent/vibrate. Refreshments. Patient resource materials
Restrooms Cell phones on silent/vibrate Refreshments Patient resource materials This presentation should not replace discussions with your healthcare provider, but seeks to provide information and resources
More informationDiagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory
Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc. Learning Objectives Compare traditional
More informationDiagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory
Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc. Learning Objectives Compare traditional
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationMultiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA
Multiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA July 13, 2015 Welcome and Introductions Anne Quinn Young, MPH Multiple Myeloma Research Foundation Norwalk, CT
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mateos M-V, Hernández M-T, Giraldo P, et al. Lenalidomide plus
More informationMinimal Residual Disease assessment in Multiple Myeloma by Next-Generation Sequencing
Minimal Residual Disease assessment in Multiple Myeloma by Next-Generation Sequencing Prof Hervé AVET-LOISEAU, : MD, PhD Institut Universitaire du Cancer Toulouse, France MRD Meta-Analysis in Myeloma Nikhil
More informationSerum heavy-light chain analysis (Hevylite): clinical applications for multiple myeloma
Serum heavy-light chain analysis (Hevylite): clinical applications for multiple myeloma Kelly Endean PhD Scientific Affairs Manager, The Binding Site Focus of this talk An introduction to heavy-light chain
More informationJune Laboratory Evaluation of Plasma Cell Neoplasms Stan McCormick, MD
June 2011 Laboratory Evaluation of Plasma Cell Neoplasms Stan McCormick, MD In this issue we review the laboratory work up of patients suspected of having a plasma cell neoplasm. As the range in clinical
More informationSmoldering Multiple Myeloma
Smoldering Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationWhat do you do, with an M protein?
What do you do, with an M protein? Cancer Day for Primary Care Emily Rimmer MD FRCPC January 31, 2014 emily.rimmer@cancercare.mb.ca Disclosure of Potential for Conflict of Interest Name of presenter: Emily
More informationUAMS ADVANCED DIAGNOSTICS FOR ADVANCING CURE
UAMS ADVANCED DIAGNOSTICS FOR ADVANCING CURE advanced diagnostics for advancing cure Multiple myeloma (myeloma) is a complex cancer that can be diffcult to diagnose and challenging to treat. Every case
More informationThe Importance of Establishing Baseline Disease Characteristics in Myeloma Diagnosis and Management
I am Dr. Brian Durie at Cedars Sinai Medical Center, Los Angeles. I am also chairman of the International Myeloma Foundation, and I am very pleased today to be participating in this program with my friend
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm Myeloma 101: Disease Overview Hans Lee, MD Assistant Professor Department of Lymphoma/Myeloma University of Texas MD Anderson Cancer Center No Disclosures
More informationStandardization of Minimal Residual Disease Testing in Multiple Myeloma
Standardization of Minimal Residual Disease Testing in Multiple Myeloma Linda B. Baughn 1 and Michael A. Linden 2 * Multiple myeloma (MM) 3 is an incurable neoplasm of the bone marrow characterized by
More informationHEALTHTREE QUESTIONNAIRE
HEALTHTREE QUESTIONNAIRE PLEASE ASK YOUR NURSE OR HEALTH CARE TEAM IF YOU NEED HELP COMPLETING THE FORM Name Date: PRIOR MYELOMA START STOP TYPE OF DID THE DOCTOR ADD OR REMOVE A DRUG OR CHANGE YOUR DOSE?
More informationTHE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA. themmrf.org
THE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA themmrf.org ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by identical twin sisters
More informationDiagnosis and Current Standard Treatments for Multiple Myeloma. Natalie S. Callander, M.D Professor of Medicine
Diagnosis and Current Standard Treatments for Multiple Myeloma Natalie S. Callander, M.D Professor of Medicine Goals Introduce and/or compliment understanding of plasma cell disorders-mgus, SMM and symptomatic
More informationبسم اهلل الرمحن الرحيم
بسم اهلل الرمحن الرحيم Definition Multiple myeloma is a neoplastic plasma cell dyscrasia (PCD) that generally produced a monoclonal immunoglobulin protein, characterized by a clinical pentad: (a) anemia;
More informationUnderstanding Lab Values in Multiple Myeloma
Understanding Lab Values in Multiple Myeloma A reference guide to the common laboratory tests used in the diagnosis and monitoring of multiple myeloma Differential Diagnosis Multiple Myeloma (MM) Is a
More informationDIAGNOSIS OF MYELOMA BASED ON THE 2014 INTERNATIONAL MYELOMA WORKING GROUP
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Majalah Patologi Klinik Indonesia dan Laboratorium Medik Page 196 2018 March; 24(2): 196-200 p-issn 0854-4263 e-issn 2477-4685 Available
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Transformed Pre- Ig Surface Surface Secreted B- ALL Macroglobulinemia Myeloma
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationFreelite & Hevylite. Together Freelite & Hevylite catch more monoclonal gammopathy patients. The Specialist Protein Company
Freelite & Hevylite Together Freelite & Hevylite catch more monoclonal gammopathy patients The Specialist Protein Company Freelite The Freelite assay is composed of two sensitive and specific polyclonal
More informationSalvage Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma
Salvage Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Arnon Nagler, M.D., M.Sc Director Hematology Division BMT and Cord Blood Bank Chair Israeli BMT Association Chaim Sheba Medical Center,
More informationMultiple Myeloma Training for Physicians 2018
Multiple Myeloma Training for Physicians 2018 Objective and Aim: The National University Cancer Institute, Singapore (NCIS) is the only public cancer centre in Singapore treating both paediatric and adult
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL GENERAL FORMS AND GUIDELINES MYELOMA FORMS CHAPTER 16D REVISED: SEPTEMBER 2016
MYELOMA FORMS The guidelines and figures below are specific to Myeloma studies. The information in this manual does NOT represent a complete set of required forms for any myeloma study. Please refer to
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation in the Era of Novel Therapies Larry Anderson, MD, PhD Multiple Myeloma and Stem Cell Transplant
More informationMeeting report of the 5th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma
DOI 10.1007/s00432-015-1993-3 REVIEW CLINICAL ONCOLOGY Meeting report of the 5th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma Maximilian Merz
More informationApplicazioni della misura delle Free Light Chain nella pratica clinica. Maria Teresa Petrucci
Applicazioni della misura delle Free Light Chain nella pratica clinica Maria Teresa Petrucci Serum free light chain immunoassay Heavy chain Kappa Light chain Hidden surface Lambda Exposed surface Serum
More informationUNDERSTANDING THE CLONOSEQ ASSAY
FOR HEALTHCARE PROVIDERS UNDERSTANDING THE CLONOSEQ ASSAY Clonality (ID) and Tracking (MRD) Reports clonoseq is an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies
More informationWG-ICQA Harmonisation of Interpretive Commenting EQA
WG-ICQA Harmonisation of Interpretive Commenting EQA WG-ICQA Subgroup: Harmonisation of reporting of protein electrophoresis and serum FLC, and quantification of small monoclonal proteins Improved patient
More information2111: ALL Post-HCT. Add/ Remove/ Modify. Manual Section. Date. Description. Comprehensive Disease- Specific Manuals
2111: ALL Post-HCT The Acute Lymphoblastic Leukemia Post-HCT Data Form is one of the Comprehensive Report Forms. This form captures ALL-specific post-hct data such as: planned treatments post-hct, the
More informationABC of laboratory techniques for diagnosis and follow-up of monoclonal gammopathies. An Hendrickx MSc. Scientific Advisor
ABC of laboratory techniques for diagnosis and follow-up of monoclonal gammopathies An Hendrickx MSc. Scientific Advisor In this talk introduction biology of free light chains laboratorium investigation
More informationacute leukemia precursor chronic leukemia lymphoma
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated t d Pre- B-cell B-cell Ig Surface Transformed B-cell Surface Plasma cell Secreted Major malignant counterpart
More informationCitation for published version (APA): Hovenga, S. (2007). Clinical and biological aspects of Multiple Myeloma s.n.
University of Groningen Clinical and biological aspects of Multiple Myeloma Hovenga, Sjoerd IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationFour Experts Debate Aggressive Treatment Approaches and the Goal of Complete Response Recorded on April 19, 2014
Patient Power Knowledge. Confidence. Hope. Toward a Cure for Multiple Myeloma: Four Experts Debate Aggressive Treatment Approaches and the Goal of Complete Response Recorded on April 19, 2014 Gareth Morgan,
More informationElevated Immunoglobulins and Paraproteins
Elevated Immunoglobulins and Paraproteins NWL Pathology GP Study Afternoon Thursday 19 th October 2017 Dr Aristeidis Chaidos Consultant Haematologist and Honorary Senior Clinical Lecturer Hammersmith Hospital,
More informationYour Test Results. Understanding. Multiple Myeloma Cancer of the Bone Marrow. A publication of the International Myeloma Foundation
Multiple Myeloma Cancer of the Bone Marrow Understanding Your Test Results U-YTR_EN_2018_j1 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800.452.CURE (USA & Canada) 818.487.7455
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Pr e- Transformed Ig Su rf ace Su rf ace Secre ted Myelom a
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pr e- B-ce ll B-ce ll Transformed B-ce ll Plasma cell Ig Su rf ace Su rf ace Secre ted Major malignant
More informationUnderstanding MGUS and Smoldering Multiple Myeloma
Multiple Myeloma Cancer of the Bone Marrow Understanding MGUS and Smoldering Multiple Myeloma u-mgus+smm_en_2017_i1 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE
More informationChange Summary - Form 2116 (R3) 1 of 6
Change Summary - Form 2116 (R3) 1 of 6 Form Question Number (r3) Question Text Change Type Description New Text Previous Text Previous Question Number (r2) 2116 Today's date: Removed "Today's date:" was
More informationMeasuring Myeloma in the LAB. BL Ferry Clinical Lead Sept 15 th 2014
Measuring Myeloma in the LAB BL Ferry Clinical Lead Sept 15 th 2014 Oxford Immunology Laboratory Clinical Immunology Churchill WHAT DO WE MEASURE AND HOW? Clinical Immunology Churchill Serum proteins Proteins
More informationMedical Policy Manual. Topic: Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification. Date of Origin: January 2014
Medical Policy Manual Topic: Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification Date of Origin: January 2014 Section: Genetic Testing Last Reviewed Date: January
More informationYour Test Results. Understanding. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow
Multiple Myeloma Cancer of the Bone Marrow Understanding Your Test Results u-ytr_en_2017_h4 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada)
More informationSingle Tube, Six-Color Flow Cytometric Analysis Is a Sensitive and Cost-Effective Technique for Assaying Clonal Plasma Cells
Hematopathology / Flow Cytometric Analysis of Clonal Plasma Cells Single Tube, Six-Color Flow Cytometric Analysis Is a Sensitive and Cost-Effective Technique for Assaying Clonal Plasma Cells Derek K. Marsee,
More informationParameswaran Hari Medical College of Wisconsin Milwaukee
Multiple Myeloma Linking the clinical course to report forms Parameswaran Hari Medical College of Wisconsin Milwaukee 45,000 Annual Numbers of Blood and Marrow Transplants Worldwide 1970-2003 40,000 Number
More informationTreatment of Multiple Myeloma with Stem Cell Transplantation (SCT)
Treatment of Multiple Myeloma with Stem Cell Transplantation (SCT) Görgün Akpek, MD, MHS Director, SCT and Cellular Therapy Program Banner MD Anderson Cancer Center GAkpek@mdanderson.org MULTIPLE MYELOMA
More information1 st European Myeloma Network Meeting
PRELIMINARY PROGRAM 1 st European www.emn2018.com TIMETABLE Thursday, April 19, 2018 Friday, April 20, 2018 Saturday, April 21, 2018 8.00-9.00 MEET THE EXPERTS 8.00-9.00 MEET THE EXPERTS 11.30-11.40 OPENING
More informationA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma Paul G. Richardson, M.D., Bart Barlogie, M.D., Ph.D., James Berenson, M.D., Seema Singhal, M.D., Sundar Jagannath, M.D., David Irwin, M.D.,
More informationManaging Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know
Managing Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know Disclaimer: The information within this CME/CE activity is for continuing education purposes only, and is not intended
More informationJanuary Northside Multiple Myeloma Support Group Meeting January 5, 2019
January 2019 Northside Multiple Myeloma Support Group Meeting January 5, 2019 Dr. Lonial welcomed 70 people to the conference center. He reported that the Winship team is growing and they were at ASH reporting
More informationEmerging treatments in Multiple myeloma. Josh Veatch Damian Green
Emerging treatments in Multiple myeloma Josh Veatch Damian Green Emerging treatments in multiple myeloma Introduction Daratumumab Elotuzumab PD 1 inhibitors HDAC inhibitors Other emerging therapies in
More informationSmouldering myeloma. Myeloma Infosheet Series. Other related conditions. Infoline:
Smouldering myeloma This Infosheet provides information on what smouldering myeloma is, how it is diagnosed, what the treatment is and will explain the link between smouldering myeloma and active myeloma.
More informationHandout for lecture on plasma cell neoplasms presented by Rob McKenna
Handout for lecture on plasma cell neoplasms presented by Rob McKenna The following slides represent a near final version of the presentation that will be given in Maui, January 23,2018. Minor changes
More informationOperator Greetings, and welcome to the Living With Myeloma: Managing Side Effects and Quality of Life telephone and Web education program.
WELCOME AND INTRODUCTION Operator Greetings, and welcome to the Living With Myeloma: telephone and Web education program. It is now my pleasure to introduce your moderator,. Thank you, Ms. Figueroa-Rivera.
More informationAVANÇOS NO DIAGNÓSTICO E CLASSIFICAÇÃO IMUNOFENOTIPICA DE LEUCEMIAS LINFOCITICAS CRÓNICAS B
AVANÇOS NO DIAGNÓSTICO E CLASSIFICAÇÃO IMUNOFENOTIPICA DE LEUCEMIAS LINFOCITICAS CRÓNICAS B CANCER RESEARCH CENTER IBSAL-UNIVERSITY OF SALAMANCA/CSIC HEMO 2016 Congreso Brasileiro de Hematologia, Hemoterapia
More informationUAMS. Forging the path to cure through exploration and discovery
UAMS Forging the path to cure through exploration and discovery Forging the Path to cure through exploration and discovery Multiple myeloma, a cancer of plasma cells in bone marrow, is a biologically complex
More informationFreelite for Measurement of Urine-Free Light Chains in Monoclonal Gammopathies
Freelite for Measurement of Urine-Free Light Chains in Monoclonal Gammopathies Montgomery Lobe, MD, and Donald Pasquale, MD Abstract Monoclonal gammopathies are characterized by production of monoclonal
More informationFreelite & Hevylite. Together Freelite & Hevylite provide optimal detection of monoclonal gammopathies
Freelite & Hevylite Together Freelite & Hevylite provide optimal detection of monoclonal gammopathies Monoclonal Gammopathy Monoclonal gammopathies are diseases of the bone marrow and are associated with
More information08:40-08:45 Introduction Robert A. Kyle (Rochester)
Friday, October 5, 2018 08:30 08:40 Welcome SESSION I Smoldering Myeloma Chairs: Robert A. Kyle (Rochester) 4 th INTERNATIONAL CONFERENCE ON MULTIPLE MYELOMA Mandelieu, France October 5-7, 2018 Chairs
More informationThe MMRF CoMMpass Study SM in Context
The MMRF CoMMpass Study SM in Context A Look at the Past, Present, and Future of Multiple Myeloma Research themmrf.org Table of Contents General Overview... 3 Multiple Myeloma Research Foundation: Who
More informationMULTIPLE MYELOMA Disease Overview
Speak to a patient support nurse PH: 1.866.603.6628 Email: patientnavigator@themmrf.org MULTIPLE MYELOMA Disease Overview Place stamp here Multiple Myeloma Research Foundation 383 Main Avenue, 5th Floor
More informationMULTIPLE MYELOMA Disease Overview
MULTIPLE MYELOMA Disease Overview ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION After being diagnosed with multiple myeloma in 1998, Kathy Giusti and her sister Karen Andrews, a successful corporate attorney,
More informationMultiple Myeloma Update PMMNG 13 Feb Outline. Alfred Garfall MD Edward Stadtmauer MD
Multiple Update PMMNG 13 Feb 2016 Alfred Garfall MD Edward Stadtmauer MD Outline w Updates on existing/approved drugs for multiple myeloma w Updates on new/upcoming drugs and strategies for multiple myeloma
More informationImmunophenotyping of Peripheral Blood and Bone Marrow Cells by Flow Cytometry *Akanni EO and # Palini A.
Immunophenotyping of Peripheral Blood and Bone Marrow Cells by Flow Cytometry *Akanni EO and # Palini A. * Department of Haematology & Blood Transfusion,College of Health Science, Ladoke Akintola University
More informationDRUGS LIFESPAN FOR PATIENTS DECADE TRIPLING THE IN THE LAST SURVIVAL IMPROVEMENT
10 40 % 3 IMPROVEMENT DRUGS IN THE LAST DECADE IN 5 YEAR SURVIVAL X TRIPLING THE LIFESPAN FOR PATIENTS 4 Drugs Approved in 2015! FDA APPROVALS IN 2015 Drug FDA Approval Panobinostat (Farydak ) February
More informationManagement of AKI in Myeloma: Novel Approaches Dr Colin A Hutchison
Management of AKI in Myeloma: Novel Approaches Dr Colin A Hutchison Consultant Nephrologist, Hawke s Bay DHB, NZ Senior Lecturer, University of Birmingham, Birmingham, UK Why are nephrologists interested
More informationA Caregiver s Guide to Helping Myeloma Patients. Webinar 1, February 23, 2017 The New Normal for Caregivers of Patients With Multiple Myeloma
A Caregiver s Guide to Helping Myeloma Patients The New Normal for Caregivers of Patients With Multiple Myeloma Speakers Moderator: Mary DeRome Multiple Myeloma Research Foundation Norwalk, Connecticut
More informationMultiple myeloma Forecast DMKC Published on 07/04/2016
Multiple myeloma Forecast DMKC0157485 Published on 07/04/2016 Datamonitor Healthcare forecasts that the extended indications for these drugs will lead to considerable uptake across the treatment algorithm,
More informationDiagnosis and staging
Chapter 2 Diagnosis and staging Carlos Fernández de Larrea and Joan Bladé Diagnostic criteria Multiple myeloma (MM) is a plasma cell disorder characterized by a clonal proliferation of cells producing
More informationThank you, Lizette. I d like to add my welcome to the patients, caregivers and healthcare professionals attending the program today.
WELCOME AND INTRODUCTION Hello everyone. On behalf of The Leukemia & Lymphoma Society (LLS), a warm welcome to all of you. Special thanks to Dr. Larry Anderson for sharing his time and expertise with us
More informationCancer ImmunoTherapy Accelerator (CITA) Dr Shalini Jadeja
Cancer ImmunoTherapy Accelerator (CITA) Dr Shalini Jadeja The Vision To develop an integrative London initiative that emerges as the UK hub for immunotherapy of cancer focusing on: Safe and effective
More informationA TÉCNICA DO NGF (Next Generation Flow) PARA ESTUDO DE DRM
A TÉCNICA DO NGF (Next Generation Flow) PARA ESTUDO DE DRM CANCER RESEARCH CENTER IBSAL-UNIVERSITY OF SALAMANCA/CSIC HEMO 2016 Congreso Brasileiro de Hematologia, Hemoterapia y Terapia Celular Florianopolis,
More informationPersonalized CAR-T Immunotherapy Platform
GLP, GMP, and CLIA-Certified Lab Personalized CAR-T Immunotherapy Platform Accelerate your cancer research and drug discovery Platform Overview 1500 Existing Hybridomas and Antibody Engineering Custom
More informationMicroarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification
Medical Policy Manual Genetic Testing, Policy No. 70 Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification Next Review: January 2019 Last Review: January 2018 Effective:
More informationDARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA Data from the dose-escalation part of the FIH study Abstract #8512
DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA Data from the dose-escalation part of the FIH study Abstract #8512 Henk Lokhorst, Torben Plesner, Peter Gimsing, Hareth Nahi, Monique
More informationMultiple Myeloma Research Consortium Clinical Trial Pipeline
Multiple Myeloma Research Consortium Clinical Trial Pipeline Phase 2 Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma NCT02279394 High-Risk
More informationFlow Cytometry in the Diagnosis of Hematopoietic Neoplasia. Brent Wood MD, PhD Professor, Laboratory Medicine University of Washington, Seattle
Flow Cytometry in the Diagnosis of Hematopoietic Neoplasia Brent Wood MD, PhD Professor, Laboratory Medicine University of Washington, Seattle 1 Flow Cytometer 2 The Power of Flow Cytometry Single cell
More informationA Report on the Molly and David Bloom Chair in Multiple Myeloma Research at the Princess Margaret Cancer Centre
A Report on the Molly and David Bloom Chair in Multiple Myeloma Research at the Princess Margaret Cancer Centre April 2013 Table of Contents 1 Introduction 2 Your Support 3 Thank you 10 The Princess Margaret
More informationThis talk will cover. New insights and future directions. Dr Hannah Hunter Consultant Haematologist University Hospitals Plymouth NHS Trust
This talk will cover New insights and future directions Dr Hannah Hunter Consultant Haematologist University Hospitals Plymouth NHS Trust An overview of current research areas o Understanding who gets
More informationAdvances in B Lymphblastic Leukemia MRD. Brent Wood MD PhD Departments of Laboratory Medicine and Pathology University of Washington.
Advances in B Lymphblastic Leukemia MRD Brent Wood MD PhD Departments of Laboratory Medicine and Pathology University of Washington Measures of Response Clinical outcome OS, EFS, RFS, etc. Blast count
More informationEDUCATIONAL COMMENTARY LABORATORY EVALUATION OF IMMUNOPROLIFERATIVE DISORDERS
Commentary provided by: Louann W. Lawrence, Dr.PH, MLS (ASCP) Professor Emeritus, Retired Louisiana State University Health Sciences Center New Orleans, LA EDUCATIONAL COMMENTARY LABORATORY EVALUATION
More informationLaboratory Persistence and Clinical Progression of Small Monoclonal Abnormalities
Immunopathology / Persistence of IFE MGUS Laboratory Persistence and Clinical Progression of Small Monoclonal Abnormalities David L. Murray, MD, PhD, 1 Justin L. Seningen, MD, 1 Angela Dispenzieri, MD,
More informationMRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods
REGULAR ARTICLE MRD detection in multiple myeloma: comparison between MSKCC 1-color single-tube and EuroFlow 8-color 2-tube methods Mikhail Roshal, 1 Juan A. Flores-Montero, 2-4 Qi Gao, 1 Maesa Koeber,
More informationReport of Survey conducted by IFCC WG Harmonisation of Interpretive Commenting EQA (WG-ICQA) subgroup:
Report of Survey conducted by IFCC WG Harmonisation of Interpretive Commenting EQA (WG-ICQA) subgroup: Results of an international survey of the reporting of protein electrophoresis and serum free light
More informationPrincess Margaret Cancer Centre Multiple Myeloma Day Introduction. Anca Prica MD, MSc, FRCPC May 12, 2017
Princess Margaret Cancer Centre Multiple Myeloma Day Introduction Anca Prica MD, MSc, FRCPC May 12, 2017 Who are you? 1) Physician 2) Nurse 3) Pharmacist 4) Trainee 5) Other How many times have you been
More informationFundamentals of Next-Generation Sequencing: Technologies and Applications
Fundamentals of Next-Generation Sequencing: Technologies and Applications Society for Hematopathology European Association for Haematopathology 2017 Workshop Eric Duncavage, MD Washington University in
More informationASH 2014 Coverage: Myeloma Roundtable Discussion Recorded on December 7, 2014
ASH 2014 Coverage: Myeloma Roundtable Discussion Recorded on December 7, 2014 Robert Orlowski, MD, PhD Director of Myeloma and Professor in the Departments of Lymphoma/Myeloma and Experimental Therapeutics,
More informationTo learn more about the MMRF, visit or call Accredited by: 2015 Multiple Myeloma Reseach Foundation
ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION Shortly after being diagnosed with multiple myeloma, Kathy Giusti and her sister Karen Andrews, a successful corporate attorney, founded the MMRF in 1998
More informationInformation and resources for African Americans living with multiple myeloma and their caregivers
For African Americans living with Multiple Myeloma Information and resources for African Americans living with multiple myeloma and their caregivers Standing in the Gaap: An initiative created to help
More informationEffective Health Care Program
Comparative Effectiveness Review Number 73 Effective Health Care Program Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias Executive Summary Background
More informationTRANSCRIPT. Managing Your Myeloma Patient Education Telephone/Web Program WELCOME AND INTRODUCTION. Lizette Figueroa-Rivera, MA
WELCOME AND INTRODUCTION Lizette Figueroa-Rivera, MA Hello everyone. On behalf of The Leukemia & Lymphoma Society (LLS), a warm welcome to all of you. Special thanks to Dr. Craig Cole for sharing his time
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Jeffrey A. Zonder, MD Karmanos Cancer Institute Objectives Discuss use of standard myeloma therapies when used as therapy
More informationRef: CYT-MM-MRD. For Research Use Only. Not for use in diagnostic procedures
Ref: CYT-MM-MRD For Research Use Only. Not for use in diagnostic procedures MM MRD VIALS AND COMPENSATION TUBES ARE LYOPHILIZED PRODUCTS. READ CAREFULLY THE FOLLOWING INSTRUCTIONS FOR RECONSTITUTION: The
More information